[go: up one dir, main page]

MX2019014548A - Derivado de n2,n4-difenilprimidin-2,4-diamina, metodo para la preparacion del mismo, y una composicion farmaceutica que contiene el mismo como ingrediente activo para la prevencion o tratamiento de cancer. - Google Patents

Derivado de n2,n4-difenilprimidin-2,4-diamina, metodo para la preparacion del mismo, y una composicion farmaceutica que contiene el mismo como ingrediente activo para la prevencion o tratamiento de cancer.

Info

Publication number
MX2019014548A
MX2019014548A MX2019014548A MX2019014548A MX2019014548A MX 2019014548 A MX2019014548 A MX 2019014548A MX 2019014548 A MX2019014548 A MX 2019014548A MX 2019014548 A MX2019014548 A MX 2019014548A MX 2019014548 A MX2019014548 A MX 2019014548A
Authority
MX
Mexico
Prior art keywords
cancer
treatment
diphenylpyrimidine
prevention
same
Prior art date
Application number
MX2019014548A
Other languages
English (en)
Inventor
Lee Kwangho
Choi Gildon
Hak Chae Chong
Shin Inji
Jeong Choe Hyeon
Eun Jung Myoung
Uk Jeon Byeong
Chul Cho Byoung
Won Park Chae
Kim Hwan
Babu Duggirala Krishna
Original Assignee
Korea Res Inst Chemical Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Res Inst Chemical Tech filed Critical Korea Res Inst Chemical Tech
Publication of MX2019014548A publication Critical patent/MX2019014548A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a un derivado de N2,N4-difenilpirimidin-2,4-diamina, un método para preparar el mismo y una composición farmacéutica para la prevención o el tratamiento del cáncer, que contiene el mismo como ingrediente activo. El derivado muestra un efecto inhibidor de la actividad de EGFR relativamente débil sobre el EGFR de tipo salvaje, una alta capacidad inhibitoria en la mutación de EGFR y una alta capacidad inhibitoria incluso en la mutación FLT3 y FLT3, y por lo tanto, puede usarse eficazmente para el tratamiento del cáncer con EGFR mutación o cáncer con FLT3 o una mutación del mismo, y el derivado muestra un efecto de sinergia en el momento de la administración combinada y, por lo tanto, puede usarse eficazmente para el tratamiento de la administración combinada.
MX2019014548A 2017-06-13 2018-06-12 Derivado de n2,n4-difenilprimidin-2,4-diamina, metodo para la preparacion del mismo, y una composicion farmaceutica que contiene el mismo como ingrediente activo para la prevencion o tratamiento de cancer. MX2019014548A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20170073907 2017-06-13
KR1020170146241A KR20180135781A (ko) 2017-06-13 2017-11-03 N2,n4-디페닐피리미딘-2,4-디아민 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
PCT/KR2018/006644 WO2018230934A1 (ko) 2017-06-13 2018-06-12 N2,n4-디페닐피리미딘-2,4-디아민 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물

Publications (1)

Publication Number Publication Date
MX2019014548A true MX2019014548A (es) 2020-02-07

Family

ID=70972831

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019014548A MX2019014548A (es) 2017-06-13 2018-06-12 Derivado de n2,n4-difenilprimidin-2,4-diamina, metodo para la preparacion del mismo, y una composicion farmaceutica que contiene el mismo como ingrediente activo para la prevencion o tratamiento de cancer.

Country Status (19)

Country Link
US (2) US11253516B2 (es)
EP (1) EP3640246B1 (es)
JP (1) JP6945015B2 (es)
KR (2) KR20180135781A (es)
CN (1) CN110740999A (es)
AU (1) AU2018286361B2 (es)
BR (1) BR112019026253A2 (es)
CA (1) CA3066083C (es)
CL (1) CL2019003589A1 (es)
EA (1) EA201992722A1 (es)
ES (1) ES2969701T3 (es)
IL (1) IL271291B2 (es)
JO (1) JOP20190281A1 (es)
MX (1) MX2019014548A (es)
NZ (1) NZ760089A (es)
PL (1) PL3640246T3 (es)
SA (1) SA519410722B1 (es)
WO (1) WO2018230934A1 (es)
ZA (1) ZA201908241B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101992621B1 (ko) 2017-12-07 2019-09-27 주식회사 온코빅스 암세포 성장 억제 효과를 나타내는 신규한 피리미딘 유도체 및 그를 포함하는 약제학적 조성물
CN113747895A (zh) 2019-03-22 2021-12-03 大日本住友制药肿瘤公司 包含pkm2调节剂的组合物和用其治疗的方法
WO2020257385A1 (en) * 2019-06-20 2020-12-24 Dana-Farber Cancer Institute, Inc. Small molecule inhibitors of src tyrosine kinase
AU2020296620B2 (en) * 2019-06-20 2023-07-13 Oncobix Co.Ltd. Pyrimidine derivative inhibiting growth of cancer cell and medicinal use thereof
JP2022539208A (ja) 2019-07-03 2022-09-07 スミトモ ファーマ オンコロジー， インコーポレイテッド チロシンキナーゼ非受容体１（ｔｎｋ１）阻害剤およびその使用
KR102168179B1 (ko) 2019-10-31 2020-10-20 주식회사 온코빅스 암세포 성장 억제 효과를 나타내는 신규한 헤테로 고리 치환 피리미딘 유도체 및 그를 포함하는 약제학적 조성물
AU2020406819B2 (en) * 2019-12-16 2023-11-09 Oncobix Co., Ltd. Novel deuterium-substituted pyrimidine derivative and pharmaceutical composition comprising same
CN113896744B (zh) * 2020-07-06 2024-04-16 成都先导药物开发股份有限公司 一种选择性egfr抑制剂
KR102539755B1 (ko) * 2020-09-11 2023-06-05 제이투에이치바이오텍 (주) Egfr 돌연변이 암의 억제용 화합물 및 이들의 의약 용도
CN112390760B (zh) * 2020-10-15 2022-07-29 北京师范大学 靶向fak的化合物及其制备方法和应用
CN112239422B (zh) * 2020-10-16 2022-07-22 河北化工医药职业技术学院 一种布格替尼中间体、其盐、其制备方法以及布格替尼的制备方法
US20240091226A1 (en) * 2021-01-05 2024-03-21 Sumitomo Pharma Oncology, Inc. Forms and Formulations Of A Tyrosine Kinase Non-Receptor 1 (TNK1) Inhibitor
US20240051940A1 (en) * 2021-02-08 2024-02-15 Accutar Biotechnology Inc. Sulfonamides with egfr inhibition activities and their use thereof
KR102800635B1 (ko) * 2021-04-01 2025-04-29 주식회사 테라펙스 단백질 키나아제 저해 활성을 갖는 피리미딘 유도체 및 이를 포함하는 치료용 약학 조성물
CN117120424A (zh) * 2021-04-01 2023-11-24 泰拉佩克斯有限公司 具有抑制蛋白激酶活性的嘧啶衍生物和包括其的治疗药物组合
CA3207015A1 (en) * 2021-04-01 2022-10-06 Tae Bo Sim Pyrimidine derivative with inhibitory activity against protein kinases and therapeutic pharmaceutical composition including the same
US12297194B2 (en) 2021-04-02 2025-05-13 Bridge Biotherapeutics, Inc. N2-phenylpyrimidine-2,4-diamine compounds, and preparation methods and methods of use thereof
IL310020A (en) * 2021-07-13 2024-03-01 Korea Res Inst Chemical Tech Innovative 2,4-pyrimidine-diamine derivatives, their preparation method and pharmaceutical preparations containing them as an active substance for the prevention and treatment of cancer
US20230330112A1 (en) * 2022-04-15 2023-10-19 Bridge Biotherapeutics, Inc. Composition and treatment for cancer with mutations
WO2024106979A1 (ko) * 2022-11-17 2024-05-23 (주)팜캐드 피페리딘 유도체, 이의 염 및 이를 유효성분으로 포함하는 약학적 조성물
WO2024242360A1 (ko) * 2023-05-24 2024-11-28 주식회사 온코빅스 Alk에 의해 매개되는 암 치료제
CN116531385A (zh) * 2023-06-19 2023-08-04 中国人民解放军空军军医大学 Czc-54252在制备治疗食管鳞癌的药物中的应用
WO2025110778A1 (ko) * 2023-11-21 2025-05-30 주식회사 에스트리온 두경부암의 예방 또는 치료용 약학적 조성물
WO2025110777A1 (ko) * 2023-11-21 2025-05-30 주식회사 에스트리온 유방암의 예방 또는 치료용 약학적 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0413616B8 (pt) * 2003-08-15 2021-05-25 Irm Llc 2,4-pirimidinadiaminas, seus usos, e composição farmacêutica
GEP20125691B (en) 2006-12-08 2012-11-26 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2009127642A2 (en) * 2008-04-15 2009-10-22 Cellzome Limited Use of lrrk2 inhibitors for neurodegenerative diseases
PT2300013T (pt) 2008-05-21 2017-10-31 Ariad Pharma Inc Derivados de fósforo como inibidores de cinases
JP6317320B2 (ja) * 2012-03-15 2018-04-25 セルジーン シーエーアール エルエルシー 上皮成長因子受容体キナーゼ阻害剤の塩
KR101656382B1 (ko) 2014-02-28 2016-09-09 한국화학연구원 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물
US10058559B2 (en) * 2014-05-15 2018-08-28 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Treatment or prevention of an intestinal disease or disorder
CN106459007B (zh) 2014-06-17 2020-02-28 韩国化学研究院 嘧啶-2，4-二胺衍生物及包含其作为有效成分的抗癌用药学组合物
WO2016027904A1 (ja) 2014-08-22 2016-02-25 富士フイルム株式会社 Ｆｌｔ３変異陽性癌を処置するための医薬組成物、変異型ｆｌｔ３阻害剤およびそれらの応用
KR101789934B1 (ko) 2015-07-31 2017-10-26 중앙대학교 산학협력단 상피세포성장인자수용체 변이체를 가진 종양 진단 및 종양 성장 억제 활성을 갖는 신규 화합물 및 이를 포함하는 의학적 용도

Also Published As

Publication number Publication date
JP2020523360A (ja) 2020-08-06
EP3640246B1 (en) 2023-11-01
KR102023156B1 (ko) 2019-09-19
EP3640246A1 (en) 2020-04-22
WO2018230934A1 (ko) 2018-12-20
IL271291B (en) 2022-10-01
JOP20190281A1 (ar) 2019-12-02
US20200179384A1 (en) 2020-06-11
US20220249482A1 (en) 2022-08-11
EP3640246A4 (en) 2020-08-05
SA519410722B1 (ar) 2023-03-15
NZ760089A (en) 2022-10-28
CL2019003589A1 (es) 2020-07-03
IL271291B2 (en) 2023-02-01
AU2018286361B2 (en) 2020-11-19
IL271291A (en) 2020-01-30
EA201992722A1 (ru) 2020-04-02
CA3066083A1 (en) 2018-12-20
EP3640246C0 (en) 2023-11-01
CN110740999A (zh) 2020-01-31
KR20180135815A (ko) 2018-12-21
JP6945015B2 (ja) 2021-10-06
ZA201908241B (en) 2021-04-28
PL3640246T3 (pl) 2024-04-22
BR112019026253A2 (pt) 2020-06-23
US11253516B2 (en) 2022-02-22
ES2969701T3 (es) 2024-05-22
KR20180135781A (ko) 2018-12-21
AU2018286361A1 (en) 2020-01-16
CA3066083C (en) 2021-11-30

Similar Documents

Publication Publication Date Title
MX2019014548A (es) Derivado de n2,n4-difenilprimidin-2,4-diamina, metodo para la preparacion del mismo, y una composicion farmaceutica que contiene el mismo como ingrediente activo para la prevencion o tratamiento de cancer.
PH12019500521A1 (en) Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
WO2015194764A3 (ko) 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물
WO2016196776A3 (en) Inhibitors of bruton's tyrosine kinase
WO2016004305A3 (en) Inhibitors of bruton's tyrosine kinase
NZ733174A (en) Quinazoline derivatives used to treat hiv
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
PH12020550491A1 (en) Pharmaceutical composition for preventing or treating acute myeloid leukemia or metastatic breast cancer
MX2021013139A (es) Composicion farmaceutica para la prevencion y/o tratamiento de dermatitis atopica que comprende antagonista de interleucina 31 (il-31) como ingrediente activo.
WO2016207090A3 (en) Targeted conjugates of ksp inhibitors
WO2016126085A3 (ko) 헤테로 고리 화합물 및 그를 포함하는 약제학적 조성물
CA3010568A1 (en) Oromucosal nanofiber carriers for therapeutic treatment
MX2016008953A (es) Composiciones farmaceuticas que comprenden i5-hidroxi-eicosa- 5,8,11,13,17-pentaenoico ( 15-hepe ) y metodos para tratar el asma y trastornos pulmonares que usan las mismas.
MY200797A (en) Substituted xanthine derivatives
ZA202200511B (en) Ring-fused thiazolino 2-pyridones, methods for preparation thereof and their use in the treatment and/or prevention of tuberculosis
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
WO2016182139A3 (ko) 자근 추출물을 유효성분으로 함유하는 말초신경병증 예방, 개선 또는 치료용 조성물
TN2019000032A1 (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX394957B (es) Agente mejorador de la inmunidad contra el cancer por el antagonista de "allergin-1".
WO2015102850A3 (en) Compositions, devices and methods for treating infections
HK1246679A1 (zh) 丝虫病的治疗
PH12019502145A1 (en) Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising tiotropium as active ingredient
WO2016144704A3 (en) Heterocyclic autotaxin inhibitor compounds
SG11202112914SA (en) Pyrido-pyrimidin derivatives and pharmaceutical composition, for use in preventing or treating pi3 kinase related diseases, comprising same as active ingredient